Development and Analysis of a Stool Bank for Cancer Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04291755 |
Recruitment Status :
Recruiting
First Posted : March 2, 2020
Last Update Posted : March 6, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study is aimed at understanding the impact of gut microbiota on efficacy of cancer therapies, in particular checkpoint inhibitors, and using the resulting information to design microbial immunotherapies. Although animal models are of use to determine the influences of gut and other microbiota on cancer treatment modalities, they are limited due to differences between mouse and human physiology and immunology, as well as the inherent differences in gut microbial populations between the two mammalian organisms. Therefore, samples obtained as donations from human subjects undergoing cancer treatment are of great value for the identification and determination of bacteria and their metabolic processes that are involved in the successful cure and remission of cancer by checkpoint inhibitor therapies.
The objective of this study is to collect 3 samples each of blood, urine, and stool in subjects with cancer. This is a non-interventional, 2 site study in 100 people who are undergoing any type of cancer immunotherapy. Subjects who meet the entry criteria will provide 5 samples each of blood, urine, and stool over a 12-month period.
Condition or disease | Intervention/treatment |
---|---|
Carcinoma, Non-Small-Cell Lung Carcinoma, Colorectal | Drug: Pembrolizumab Injection |

Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Development and Analysis of a Sample Bank (Blood, Urine, and Stool) for Cancer Patients, Enabling the Systematic Study of the Effect of Blood, Urinary Tract, and Gut Microbiomes on Response to Treatment |
Actual Study Start Date : | June 28, 2019 |
Estimated Primary Completion Date : | December 31, 2020 |
Estimated Study Completion Date : | June 30, 2021 |

Group/Cohort | Intervention/treatment |
---|---|
Checkpoint inhibitor therapy
Patients will be administered a checkpoint inhibitor therapy, including but not limited to pembrolizumab, nivolumab, ipilimumab, and atlizumab, at the standard dosing regimen prescribed by their physician. Stool, blood, and urine samples will be collected from patients prior to start of treatment, and at 4 more timepoints over the next 12 months.
|
Drug: Pembrolizumab Injection
Any checkpoint inhibitor is acceptable
Other Name: nivolumab, ipilimumab, atlizumab |
- Checkpoint inhibitor response [ Time Frame: 6-12 months ]Response of the tumor to treatment, as evaluated by the iRECIST criteria
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Men or women who are ≥ 18 years old who are undergoing any type of cancer immunotherapy
- Subjects who are able to provide written informed consent
Exclusion Criteria:
- Subjects with HIV, Hepatitis B, or Hepatitis C
- Subjects without the mental capacity to complete either a written or online questionnaire, alone or with assistance, or make sound decisions
- Women who are pregnant or who plan on becoming pregnant
- Women who are nursing

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04291755
Contact: Study Coordinator | 858-682-4777 | support@persephonebiome.com |
United States, California | |
Compassionate Care Research Group, Inc. | Recruiting |
Fountain Valley, California, United States, 92708 | |
Contact: Esther Jayachandran 714-338-2154 esther@compcareresearch.com | |
Principal Investigator: Derrick Su, MD | |
United States, Florida | |
Bond and Steele Clinic, P.A. | Recruiting |
Winter Haven, Florida, United States, 33881 | |
Contact: Nikki Denmark 863-293-1191 ndenmark@bondclinic.com | |
Principal Investigator: Osama Hlalah, MD |
Responsible Party: | Persephone Biosciences |
ClinicalTrials.gov Identifier: | NCT04291755 |
Other Study ID Numbers: |
PB-002 |
First Posted: | March 2, 2020 Key Record Dates |
Last Update Posted: | March 6, 2020 |
Last Verified: | March 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Non-small cell lung cancer immunotherapy checkpoint inhibitor pembrolizumab |
nivolumab ipilimumab microbiome |
Carcinoma Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Carcinoma, Bronchogenic Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Lung Diseases Respiratory Tract Diseases |
Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Pembrolizumab Nivolumab Ipilimumab Antineoplastic Agents, Immunological Antineoplastic Agents |